Cantargia AB | July 05, 2022
Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows
Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital.
Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDAC patients as well as 30 NSCLC patients, as shared recently with scientific and clinical colleagues at the American Society for Clinical Oncology (ASCO) Annual Meeting 2022. As described in Cantargia's announcement of June 21, 2022, the principal and immediate reasons for raising primary proceeds are to enable Cantargia to build on the positive data obtained in PDAC and NSCLC and progress the late-stage clinical development of nadunolimab.
Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies – CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR – with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Molsentech | July 29, 2022
With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early stage including SARS-CoV-2.
Founded in Taiwan, the world's leading semiconductor hub, Molsentech's pivotal breakthrough was its development of a 100% semiconductor-based biosensor platform which offers valuable application in the field of healthcare for disease detection. The core technology is called Bio-FET which allows biosensors to analyse liquid-form samples by measuring the electrical signal changes caused by the interactions between detection targets and bio probes modified on the surface of biosensors. Patented in the United States, Taiwan, and China, the technology overcomes one of the biggest challenges in the industry when dealing with samples in liquid forms, interpreting the samples in 5 minutes to give immediate results.
Molsentech's bio-FET technology remains new to the biotech industry; hence, at the beginning, it mainly played a supporting role for the mainstream detection techniques, validating the detection results provided by such tests as PCR and ELISA thanks to its ultrahigh sensitivity. During COVID-19 pandemic, the Molsentech SARS-CoV-2 test chip was granted emergency use authorization (EUA) by the Food and Drug Administration to use in the manufacturing of the novel SARS-CoV-2 test kits that resulted in faster testing process and higher accuracy. This demonstrates the capability of bio-FET technology to work independently as a bio technique for molecular diagnosis. Consequently, more cooperation is under negotiation between Molsentech and other leading biotechnology companies, including but not limited to Taiwan-based ones
As its technology is now available for commercial use on a global scale, Molsentech intends to further expand its presence in the global market, first into the United States, a country with the most advanced healthcare ecosystem to bring its technology and products to the next level. "Fortunately, we got a chance to set our footprint in the United States, that would pave the way for Molsentech to move forward. We will definitely seize this opportunity to introduce how our technology can help more people," stated Dr. Chia-Jun Chu, CEO of Molsentech.
The company reported a revenue of 1 million TWD and has conducted more fundraising activities in Taiwan and the United States.
Established in Taiwan in 2014, Molsentech serves the mission of inventing an innovative biomedical platform that provides non-invasive and real-time detection of minimum pathogens. The core team includes leading experts from the Quantum Electronic Laboratory at Academia Sinica who possess exclusive skills and experience in the semiconductor industry especially with chip design/fabrication, probe molecules modification and automation bio-sensor system integration. With its continuous efforts and commitments to high product quality and innovation, the company has been rewarded with various prestigious awards and recognitions.
Aruna Bio | June 01, 2022
Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI).
The successful completion of the proposed study is intended to provide key information pertaining to AB126™ dosage, and therapeutic effects on TBI pathophysiology (edema, hemorrhage) and functional outcomes, toxicity, and potential adverse side effects.".
Aruna Bio Chief Scientific Officer, Steven Stice.
Traumatic brain injury (TBI) is a "silent epidemic" as 2.53 million patients visit the emergency department every year of which 56,800 patients die. We are pleased to receive this award from the National Institutes of Health, to further investigate the safety and efficacy of our AB126™ biologic. Our early proof of concept studies demonstrated significant efficacy in TBI indications, and the data generated from this new study is intended to support the basis for an IND submission and future clinical trials."
Stephen From, Aruna Bio's Chief Executive Officer.
About Aruna Bio
Aruna Bio is a leader in the development of neural exosomes for the treatment of neurodegenerative diseases. The company is utilizing its proprietary neural exosome platform and manufacturing capability to develop a pipeline of neural exosome-based therapeutics able to cross the blood brain barrier and enhance the body's anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders where significant unmet medical need exists today. Additionally, the company's neural exosome platform can be combined with therapeutics, such as small molecules, siRNAs and proteins, across the blood brain barrier and to the site of disease.
OliX | June 20, 2022
OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology.
mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions since their signing of memorandums of understanding in August 2021. The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
mRNA-based CRISPR/Cas9 is a powerful platform that could potentially lead to the development of treatments for incurable diseases, Once we clinically validate the technology, we plan to expand the indications of treatments to various non-hereditary eye diseases as well.”
Sun Woo Hong, Ph.D., chief executive officer of mCureX.
About OliX Pharmaceuticals Inc.
OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.
About ToolGen Inc.
ToolGen is a biotech company with the CRISPR/Cas9 core technology in gene-editing. ToolGen's mission is to provide customers with innovative human gene/cell therapies and gene-edited animals or plants. ToolGen's research and business are based on ToolGen's CRISPR/Cas9-essential patents. ToolGen is the first patent filer successfully demonstrating a CRISPR/Cas9 application in eukaryotic cells in the world. ToolGen's CRISPR patents have been registered in ten countries, including the United States, Europe, China, Australia, and Japan.